19 hours ago
1
wildpixel/iStock via Getty Images
- Bioventus (NASDAQ:BVS) said that the U.S. FDA has approved its chronic pain management devices, TalisMann and StimTrial.
- The shares of the company are up 3.8%.
- These devices are peripheral nerve stimulation solutions, used to help with chronic pain.
- The company
English (US) ·